For women with triple-negative breast cancer — one of the most aggressive and hardest-to-treat subtypes — knowing whether chemotherapy is working after just one cycle could be transformative. Currently, clinicians must often wait months and multiple treatment cycles before imaging reveals whether a regimen is effective, leaving patients on ineffective therapy longer than necessary. This trial offers a potential way to read the room far earlier.
The TNPET01 phase II trial enrolled 22 patients with stage II–III triple-negative breast cancer and randomized them to imaging with either FDG-PET (using the glucose-analog tracer fluorodeoxyglucose) or FLT-PET (using fluorothymidine, a marker of cellular proliferation). Both tracers demonstrated acceptable test-retest repeatability in the analytic validity phase. FDG was ultimately selected for the clinical validity arm based on superior image quality and broader clinical availability. In 14 patients who underwent FDG-PET across both trial phases, reductions in SUVmax and SUVmean after a single neoadjuvant chemotherapy cycle correlated significantly with mid-treatment MRI response and residual cancer burden scores at surgery — a key surrogate for long-term outcomes.
This finding adds to a growing but still contested body of evidence that metabolic imaging biomarkers can serve as early-response surrogates in breast cancer. FDG-PET has shown promise in HER2-positive and luminal subtypes, but TNBC presents particular complexity given its immune-rich microenvironment. The trial's exploratory analyses examining relationships between PET response, Ki-67 proliferation indices, and tumor-infiltrating lymphocytes are especially relevant here, potentially linking imaging dynamics to immune biology. The primary limitation is sample size — 14 evaluable patients is insufficient to establish clinical utility, and the findings are hypothesis-generating rather than practice-changing. Nonetheless, as precision oncology moves toward adaptive treatment paradigms, validating imaging tools that enable mid-course corrections after cycle one represents a clinically meaningful direction. A larger confirmatory trial would be warranted.